Aedifica (AED)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 63.45 |
|---|---|
| 52-week range | 60.35 – 80.05 |
| Return, 1 month / 3 months | −4.4% / −9.9% |
| Return, 1 year / 3 years | +7.9% / +55.7% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 18.3% |
| Worst drawdown (1 year) | -19.0% |
| Average daily value traded | 7.72M EUR |
| Dividend yield | 6.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Aedifica is a Belgian real estate company that invests in healthcare property, mainly care homes, assisted living residences and housing for older people. It owns and develops buildings that it leases to care operators, who run the facilities and provide services to residents. The company is based in Brussels and holds properties in Belgium and several other European countries, including Germany, the Netherlands, the United Kingdom and the Nordic region.
The shares are listed on the Euronext Brussels in Belgium under the code AED, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Aedifica (AED) trades on the Euronext Brussels in Belgium. It last closed at EUR 63.45 on 22 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 43 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.9% and over the last three months it fell 9.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 40 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.3% | ||
| From 52-week high | -19.9% | ||
| Momentum | 46 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.9% | ||
| 6-month return | -8.7% | ||
| 12-month return, skipping the last month | 12.9% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 18.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.0% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 7.72M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.3% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.7% |
|---|---|
| 1 month | −4.4% |
| 3 months | −9.9% |
| 6 months | −8.7% |
| 1 year | +7.9% |
| 3 years | +55.7% |
| 5 years | −25.3% |
Signals
| 50-day / 200-day average | 65.22 / 68.45 |
|---|---|
| Golden / death cross (60 days) | Death, 24 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 4.0000 |
| 15 May 2025 | EUR 3.9000 |
| 4 Jul 2024 | EUR 1.8844 |
| 17 May 2024 | EUR 1.8844 |
| 22 Jun 2023 | EUR 1.9156 |
| 12 May 2023 | EUR 1.9299 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.